Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 40, doi. 10.1007/s11899-021-00616-6
- By:
- Publication type:
- Article
Works matching IS 15588211 AND DT 2021 AND VI 16 AND IP 1
Results: 14
1
2
Targeted Therapies for Follicular Lymphoma.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 25, doi. 10.1007/s11899-021-00614-8
- By:
- Publication type:
- Article
3
Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 82, doi. 10.1007/s11899-021-00609-5
- By:
- Publication type:
- Article
4
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 45, doi. 10.1007/s11899-021-00617-5
- By:
- Publication type:
- Article
5
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 32, doi. 10.1007/s11899-021-00615-7
- By:
- Publication type:
- Article
6
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 89, doi. 10.1007/s11899-021-00612-w
- By:
- Publication type:
- Article
7
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 72, doi. 10.1007/s11899-021-00610-y
- By:
- Publication type:
- Article
8
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 97, doi. 10.1007/s11899-021-00608-6
- By:
- Publication type:
- Article
9
AYA Considerations for Aggressive Lymphomas.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 61, doi. 10.1007/s11899-021-00607-7
- By:
- Publication type:
- Article
10
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 52, doi. 10.1007/s11899-021-00606-8
- By:
- Publication type:
- Article
11
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 8, doi. 10.1007/s11899-021-00605-9
- By:
- Publication type:
- Article
12
A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 19, doi. 10.1007/s11899-021-00604-w
- By:
- Publication type:
- Article
13
High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 112, doi. 10.1007/s11899-020-00602-4
- By:
- Publication type:
- Article
14
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 1, doi. 10.1007/s11899-020-00603-3
- By:
- Publication type:
- Article